HSP90-targeted inflammation and infection imaging and therapy

Patent metadata

Field	Value
Publication number	US-11065350-B2
Application number	US-202016845372-A
Country	US
Kind code	B2
Filing date	Apr 10, 2020
Priority date	Sep 17, 2014
Publication date	Jul 20, 2021
Grant date	Jul 20, 2021

Abstract

The present invention provides new methods for inflammation and infection imaging and related medical applications thereof. In some embodiments, the present invention provides a method for the diagnosis of inflammation and/or infection. In some embodiments, the present invention provides a method for the treatment or prevention of inflammation and/or infection. In some embodiments, the present invention provides methods for monitoring the effect of inflammation and/or infection treatment, and/or methods for monitoring an inflammation and/or infection treatment regimen. In some embodiments, the present invention provides a method for selecting subjects for an inflammation and/or infection treatment. In some embodiments, the present invention provides a method for determining the dosage of a drug for the treatment of inflammation and/or infection.

First claim

The invention claimed is:

1. A method for treatment of brain inflammation comprising administering to a subject in need thereof a compound having the formula:

or a pharmaceutically acceptable salt thereof;
wherein the brain inflammation is not caused by cancer.

2. The method of claim 1 , wherein the brain inflammation is a result of brain trauma.

3. The method of claim 1 , wherein the method further comprises administration of anti-inflammatory agents, antihistamines, immunosuppressive agents, anti-viral agents, anti-fungal agents, antibacterial agents, anti-parasitic agents, or a combination thereof.

4. The method of claim 3 , wherein administration of the anti-inflammatory agents, antihistamines, immunosuppressive agents, anti-viral agents, anti-fungal agents, antibacterial agents, anti-parasitic agents, or a combination thereof is subsequent to or prior to the administration of a compound having the formula:

or a pharmaceutically acceptable salt thereof.

5. A method for treatment of inflammation comprising administering to a subject in need thereof a compound having the formula:

or a pharmaceutically acceptable salt thereof;
wherein the inflammation is not caused by cancer.

6. The method of claim 5 , wherein the method further comprises administration of anti-inflammatory agents, antihistamines, immunosuppressive agents, anti-viral agents, anti-fungal agents, antibacterial agents, anti-parasitic agents, or a combination thereof.

7. The method of claim 6 , wherein administration of the anti-inflammatory agents, antihistamines, immunosuppressive agents, anti-viral agents, anti-fungal agents, antibacterial agents, anti-parasitic agents, or a combination thereof is subsequent to or prior to the administration of a compound having the formula:

or a pharmaceutically acceptable salt thereof.

8. A method for treatment of lung inflammation comprising administering to a subject in need thereof a compound having the formula:

or a pharmaceutically acceptable salt thereof;
wherein the inflammation is not caused by cancer.

9. The method of claim 8 , wherein the lung inflammation is a result of a lower or upper respiratory tract infection.

10. The method of claim 9 , wherein the lower or upper respiratory tract infection is a viral infection.

11. The method of claim 8 , wherein the subject is suffering from SARS or a common cold.

12. The method of claim 8 , wherein the subject has a pulmonary infiltrate.

13. The method of claim 8 , wherein the method further comprises administration of anti-inflammatory agents, antihistamines, immunosuppressive agents, anti-viral agents, anti-fungal agents, antibacterial agents, anti-parasitic agents, or a combination thereof.

14. The method of claim 13 , wherein administration of the anti-inflammatory agents, antihistamines, immunosuppressive agents, anti-viral agents, anti-fungal agents, antibacterial agents, anti-parasitic agents, or a combination thereof is subsequent to or prior to the administration of a compound having the formula:

or a pharmaceutically acceptable salt thereof.

15. A method for treatment of a viral infection comprising administering to a subject in need thereof a compound having the formula:

or a pharmaceutically acceptable salt thereof.

16. The method of claim 15 , wherein the viral infection is a lower or upper respiratory tract infection.

17. The method of claim 15 , wherein the subject is suffering from SARS or a common cold.

18. The method of claim 15 , wherein the subject has a pulmonary infiltrate.

19. The method of claim 15 , wherein the method further comprises administration of anti-inflammatory agents, antihistamines, immunosuppressive agents, anti-viral agents, anti-fungal agents, antibacterial agents, anti-parasitic agents, or a combination thereof.

20. The method of claim 19 , wherein administration of the anti-inflammatory agents, antihistamines, immunosuppressive agents, anti-viral agents, anti-fungal agents, antibacterial agents, anti-parasitic agents, or a combination thereof is subsequent to or prior to the administration of a compound having the formula:

or a pharmaceutically acceptable salt thereof.

Assignees

• Memorial Sloan Kettering Cancer Center

Inventors

• Dunphy Mark
• Chiosis Gabriela

Classifications

• A61B6/503

  for diagnosis of the heart · CPC title

• A61K51/08

  Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins} · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K49/1884

  Nanotubes, nanorods or nanowires · CPC title

• A61B5/441

  Skin evaluation, e.g. for skin disorder diagnosis · CPC title